{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:36:30Z","timestamp":1764020190556,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.nrl.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T09:09:21Z","timestamp":1520586561000},"page":"115-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Estudio observacional multic\u00e9ntrico espa\u00f1ol sobre el empleo de f\u00e1rmacos antiepil\u00e9pticos en consultas de neurolog\u00eda"],"prefix":"10.1016","volume":"35","author":[{"given":"J.M.","family":"Mercad\u00e9 Cerd\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"L\u00f3pez Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Serrano Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Castro Vilanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Campos Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Querol Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2018.01.011_bib0290","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2018.01.011_bib0295","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1528-1157.1997.tb01224.x","article-title":"ILAE Commission Report. Commission on European Affairs: Appropriate Standards of Epilepsy Care Across Europe. ILAE Commission Report","volume":"38","author":"Brodie","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0300","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/epi.13201","article-title":"Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Advocacy Europe Task Force","volume":"56","author":"Baulac","year":"2015","journal-title":"Epilepsia"},{"issue":"602710","key":"10.1016\/j.nrl.2018.01.011_bib0305","article-title":"Adult Prevalence of Epilepsy in Spain: EPIBERIA, a population-based study","volume":"2015","author":"Serrano Castro","year":"2015","journal-title":"Scientific World Journal"},{"key":"10.1016\/j.nrl.2018.01.011_bib0310","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/epi.12557","article-title":"Antiepileptic drug use in sevenelectronic health record databases in Europe: A methodologic comparison","volume":"55","author":"De Groot","year":"2014","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1016\/j.nrl.2018.01.011_bib0315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1528-1157.43.s.4.3.x","article-title":"Economic evaluation of epilepsy treatment: A review of the literature","volume":"43","author":"Heaney","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0320","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.seizure.2016.08.010","article-title":"Outcomes in newly diagnosed epilepsy in adolescents and adults: Insights across a generation in Scotland","volume":"44","author":"Brodie","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.nrl.2018.01.011_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11370","article-title":"A randomized controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. THE SANAD trial","volume":"11","author":"Marson","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.nrl.2018.01.011_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9150","article-title":"Clinical effectiveness, tolerability and cost-effectiviness of newer drugs for epilepsy in adults: A systematic review and economic evaluation","volume":"9","author":"Wilby","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.nrl.2018.01.011_bib0335","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0340","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE oficial report: A practical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0345","doi-asserted-by":"crossref","unstructured":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30(4):389-399.","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"10.1016\/j.nrl.2018.01.011_bib0350","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1528-1167.2011.03041.x","article-title":"The etiologic classification of epilepsy","volume":"52","author":"Shorvon","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0355","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"551","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0360","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0013-9580.2004.14103.x","article-title":"Direct cost of medical management of epilepsy among adults in Italy: A Prospective Cost-of-Illness Study (EPICOS)","volume":"45","author":"Beghi","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0365","doi-asserted-by":"crossref","unstructured":"Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34: 92-596.","DOI":"10.1111\/j.1528-1157.1993.tb00433.x"},{"key":"10.1016\/j.nrl.2018.01.011_bib0370","unstructured":"WHO Collaborating Centre for Drugs Statistics Methodology. ATC\/DDD Index [consultado 20 Dic May 2017; \u00faltima actualizaci\u00f3n 20 Dic 2017]. Disponible en: http:\/\/www.whocc.no\/atc_ddd_Index"},{"key":"10.1016\/j.nrl.2018.01.011_bib0375","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.03.003","article-title":"The descriptive epidemiology of epilepsy\u2014A review","volume":"85","author":"Banerjee","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.nrl.2018.01.011_bib0380","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1528-1157.1997.tb01075.x","article-title":"Prognosis of epilepsy: A review and further analysis of the first 9years of the British National General Practice Study of Epilepsy, a prospective population-based study","volume":"38","author":"Cockerell","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0385","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s004150170091","article-title":"Prevalence of epilepsy in northeast Madrid","volume":"248","author":"Luengo","year":"2001","journal-title":"J. Neurol"},{"key":"10.1016\/j.nrl.2018.01.011_bib0390","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eplepsyres.2012.05.008","article-title":"Prevalence and clinical characteristics of epilepsy in the South of Spain","volume":"102","author":"Garcia Martin","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.nrl.2018.01.011_bib0395","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/epi.12469","article-title":"Clinical characteristics of patients with treated epilepsy in Korea: A nationwide epidemiologic study","volume":"55","author":"Kim","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0400","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4065\/71.6.576","article-title":"Descriptive epidemiology of epilepsy: Contributions of population-based studies from Rochester, Minnesota","volume":"71","author":"Hauser","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.nrl.2018.01.011_bib0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2007.00992.x","article-title":"Refractory epilepsy: Clinical overview","volume":"48","author":"French","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0410","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1528-1157.1993.tb02126.x","article-title":"Some aspects of prognosis in the epilepsies: A review","volume":"34","author":"Sander","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0415","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/epi.12175","article-title":"Road to refractory epilepsy: The Glasgow story","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0420","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.seizure.2016.08.010","article-title":"Outcomes in newly diagnosed epilepsy in adolescents and adults: Insights across a generation in Scotland","volume":"44","author":"Brodie","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.nrl.2018.01.011_bib0425","doi-asserted-by":"crossref","first-page":"449","DOI":"10.33588\/rn.4608.2008020","article-title":"Estudio farmacoepidemiol\u00f3gico del consumo de f\u00e1rmacos antiepil\u00e9pticos (1992-2004)","volume":"46","author":"Abasolo Osinaga","year":"2008","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrl.2018.01.011_bib0430","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","article-title":"Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications","volume":"72","author":"Baftiu","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nrl.2018.01.011_bib0435","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":"Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population","volume":"95","author":"Landmark","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.nrl.2018.01.011_bib0440","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993-2008: Cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.nrl.2018.01.011_bib0445","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.yebeh.2013.03.007","article-title":"Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany","volume":"27","author":"Strzelczyk","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrl.2018.01.011_bib0450","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblended randomized controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2018.01.011_bib0455","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbamacepine, or topiramate for treatment of partial epilepsy: an unblended randomized controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2018.01.011_bib0460","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1528-1167.2007.01172.x","article-title":"Evidence-based epileptology, randomized controlled trials, and SANAD: A critical clinical view","volume":"48","author":"Panayiotopoulos Ch","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0465","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: An unblinded, randomised,twoparallelgroup, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrl.2018.01.011_bib0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2013.11.016","article-title":"Prospective audits with newer antiepileptic drugs in focal epilepsy: Insights into population responses?","volume":"31","author":"Brodie","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrl.2018.01.011_bib0475","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/archneurol.2010.49","article-title":"Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy","volume":"67","author":"Arif","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrl.2018.01.011_bib0480","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1528-1167.2009.02299.x","article-title":"Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: Systematic review and meta-analysis","volume":"51","author":"Beyenburg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0485","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Update ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic sezures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0490","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000123693.82339.FC","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2018.01.011_bib0495","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2018.01.011_bib0575","unstructured":"National Institute for Health and Clinical Excellence (NICE Guidance CG137). Epilepsies: Diagnosis and Management [consultado 22 Jun 2017; \u00faltima actualizaci\u00f3n Feb 2016]. Disponible en:http:\/\/www.nice.org.uk\/."},{"key":"10.1016\/j.nrl.2018.01.011_bib0505","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nrl.2014.03.003","article-title":"Pronostico de la epilepsia. Inicio del tratamiento cr\u00f3nico farmacol\u00f3gico","volume":"30","author":"Mercad\u00e9 Cerd\u00e1","year":"2015","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.nrl.2018.01.011_bib0510","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nrl.2014.04.012","article-title":"Epilepsia resistente a f\u00e1rmacos, concepto y alternativas terap\u00e9uticas","volume":"30","author":"L\u00f3pez Gonzalez","year":"2015","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.nrl.2018.01.011_bib0515","unstructured":"Gu\u00eda Andaluza de Epilepsia 2015. Diagnostico y tratamiento de la epilepsia en ni\u00f1os y adultos. p. 173-219. [consultado 22 May 2017]. Disponible en: http:\/\/www.sade.org.es"},{"key":"10.1016\/j.nrl.2018.01.011_bib0520","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S1474-4422(04)00882-8","article-title":"Efficacy and tolerability of the new antiepileptic drugs: Comparison of two recent guidelines","volume":"3","author":"Beghi","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2018.01.011_bib0525","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second-and third-generation antiepileptic drugs","volume":"10","author":"Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.nrl.2018.01.011_bib0530","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00228-017-2245-z","article-title":"Tolerability of new antiepileptic drugs: A network meta-analysis","volume":"73","author":"Zaccara","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nrl.2018.01.011_bib0535","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1528-1167.2012.03528.x","article-title":"The somatic comorbidity of epilepsy: A weighty but often unrecognized burden","volume":"53","author":"Gaitatzis","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0540","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: Current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2018.01.011_bib0545","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.seizure.2015.02.019","article-title":"Major congenital malformations in children of women with epilepsy","volume":"28","author":"Tomson","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.nrl.2018.01.011_bib0550","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/14740338.2015.1084288","article-title":"Fetal safety of old and new antiepileptic drugs","volume":"14","author":"Verrotti","year":"2015","journal-title":"Expert Opin, Drug Saf"},{"key":"10.1016\/j.nrl.2018.01.011_bib0555","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). \u00c1cido valproico: nuevas recomendaciones de uso en ni\u00f1as y mujeres con capacidad de gestaci\u00f3n [consultado 1 Mayo 2017]. Disponible en: www.aemps.gob.es"},{"key":"10.1016\/j.nrl.2018.01.011_bib0560","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/j.1528-1167.2007.01251.x","article-title":"Estimating the cost of epilepsy in Europe: A review with economic modeling","volume":"48","author":"Pugliatti","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrl.2018.01.011_bib0565","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/11597110-000000000-00000","article-title":"The cost effectiviness of newer epilepsy treatments. A review of the literature on partial-onset seizures","volume":"30","author":"Bolin","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.nrl.2018.01.011_bib0570","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00023210-200418100-00001","article-title":"Prescribing antiepileptic drugs. Should patients be switched on the basis of cost?","volume":"18","author":"Jobst","year":"2004","journal-title":"CNS Drugs"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485318300331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485318300331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:11:04Z","timestamp":1759324264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485318300331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0213485318300331"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2018.01.011","relation":{},"ISSN":["0213-4853"],"issn-type":[{"type":"print","value":"0213-4853"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estudio observacional multic\u00e9ntrico espa\u00f1ol sobre el empleo de f\u00e1rmacos antiepil\u00e9pticos en consultas de neurolog\u00eda","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}